Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Smallcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emcure Pharmaceuticals' step-down subsidiary Mantra Pharma Inc. acquired 100% of Cutimed Inc., a Canadian company engaged in cosmetics and dermatological products, for CAD $ 5.05 million in cash. Cutimed had annual turnover of CAD $ 2.8 million (FY2025) and has been operating since 2011. Immediately after the acquisition on April 1, 2026, Cutimed was amalgamated with Mantra Pharma Inc. through a short-form procedure under Canadian law. The transaction was not a related party transaction and is aligned with Emcure's core business strategy to strengthen its Canadian dermatological and cosmetic portfolio. No change in Emcure's shareholding pattern will occur.
Positive signal for shareholders as the acquisition consolidates Emcure's Canadian operations and expands its dermatology and cosmetics product portfolio. The deal is not expected to materially impact financials given Cutimed's small size relative to Mantra (CAD $ 81 million turnover).